What is the maximum fair price?

The maximum fair price is the price Medicare sets for a drug it selected for negotiation. It is a ceiling rather than a market price. For the drugs on the list, no Part D plan and no patient pays more than this number, and it takes effect on a fixed date the government publishes years ahead.

The word doing the most work is "fair," and it is worth slowing down on. A reader who meets the phrase in a company's annual report can hear it as a finding, as though a regulator studied the drug and decided what a fair price would be. The statute means something narrower. Under 42 U.S.C. 1320f, the maximum fair price is defined as "the price negotiated" under the program and updated each year. Fairness is asserted in the name. What the law fixes is a number and a ceiling.

The negotiation has a floor under the company's feet

A negotiation implies a party that can say no. A drug maker can decline the government's price, and then 26 U.S.C. 5000D applies: an excise tax on every sale of that drug for as long as the company stays out of the program. The tax rises with time. It is 65 percent for the first ninety days, then 75, then 85, then 95 percent for every day after that. Those percentages are not taken off the price. The statute sets the tax so that the percentage describes the ratio of the tax to the sum of the tax and the price, which means the top rate is a tax of roughly nineteen times the drug's sales price. The only way to avoid it is to stop selling through Medicare and Medicaid at all. Bristol Myers Squibb, in its own filing, drops the word negotiation and calls the program government price setting.

The ceiling is the number to read

The negotiated price cannot exceed a cap, and the cap is a fixed share of a benchmark called the non-Federal average manufacturer price, adjusted for inflation. 42 U.S.C. 1320f-3 sets that share by how long the drug has been on the market:

• 75 percent for a short-monopoly drug, meaning fewer than 12 years since approval or licensure.
• 65 percent for an extended-monopoly drug, at least 12 but fewer than 16 years.
• 40 percent for a long-monopoly drug, 16 years or more.

So the discount a company faces is not a surprise the reader has to wait for. The older the drug, the deeper the mandated cut, and the schedule is written down. A drug that crosses sixteen years while still on the list moves from a floor of 65 percent of the benchmark to 40 percent, a step change the company can see coming.

Why a pill is treated differently from a biologic

The clock that decides when a drug becomes eligible runs at two speeds. 42 U.S.C. 1320f-1 makes a small-molecule drug eligible for selection once at least 7 years have passed since its FDA approval, and a biologic once at least 11 years have passed since its licensure. Selection comes first, and the negotiated price begins two years later, so the numbers a shareholder should carry are closer to nine years for a pill and thirteen for a biologic.

That gap matters because a small molecule can hit its maximum fair price well before it hits its patent cliff. A company can hold real patent protection into the 2030s and still take a government-set price years earlier. When a filing says a drug is protected until a distant date, the maximum fair price is a separate erosion that arrives on its own schedule. It sits in front of the loss of exclusivity, not after it.

What the headline discount does not say

The first prices drew headlines about cuts of well over half off list price, and those numbers are real. They are also the wrong denominator for a revenue estimate. Companies already pay large rebates, so the price a drug actually earns is far below its list price before any negotiation happens. The maximum fair price replaces that already-discounted net price, not the sticker.

Medicare's own math shows the gap. CMS estimated that if the first ten negotiated prices had been in effect in 2023, they would have saved an estimated $6 billion in net covered prescription drug costs, "which would have represented 22% lower net spending in aggregate." A 22 percent cut to net spending is a serious number. It is also a long way from the headline discount off list, and the difference is the rebates that were already there. When you read a percentage cut, check whether it is measured against list or against net before you multiply it by a company's sales.

What the company says about it

Bristol Myers Squibb is a clean example because it names its own drugs and dates. Its annual report records that the government announced the maximum fair price for a thirty-day supply of Eliquis, effective January 1, 2026, and for Pomalyst, effective January 1, 2027, and that in January 2026 it selected Orencia for prices beginning in 2028. The company keeps the terms in quotation marks throughout. Then it states the risk plainly: further selections or a renegotiation "could, among other things, accelerate revenue erosion prior to expiry of intellectual property protections," and that the changes "may result in a material impact" on results.

That last sentence is the translation. A price cut Medicare frames as savings is, in the seller's own filing, revenue erosion that arrives before the patent expires. Both descriptions are of the same event. The reader's job is to hold them at once.

What to check

• List or net. A headline discount is almost always off list price. The revenue that moves is off the net price, which is lower, and the company's filings are where the gap lives.
• The drug's age. Cross sixteen years on the list and the ceiling drops from 65 to 40 percent of the benchmark. The date is arithmetic, not a forecast.
• Pill or biologic. A small molecule is exposed years earlier than a biologic, and often before its patent cliff, so a distant exclusivity date can understate the risk.
• How much of the drug is Medicare. The maximum fair price only touches the Medicare channel. A drug that sells mostly to commercial payers or outside the United States is less exposed than its place on the list suggests.
• The verb in the filing. "May result in a material impact" and "continue to evaluate" are management telling you how much it has quantified. Compare the language across a company's products and across its filings over time.

This is analysis, not investment advice. Every figure above comes from the statute, from Medicare's own fact sheet, or from the company's own annual report, linked at the point it is used.